Carl Zeiss Meditec : Q1 review – Bottom line beat driven by Microsurgery
>Q1 review – Beat on the bottom line - Q1 2024 revenues € 475.0m (+1.0% y-o-y) were driven by cc growth of c. 3.3% and a forex headwind of 230bp, or 0%/+2% vs ODDO BHF/consensus. EBIT of € 43.5m (-27.9% y-o-y, margin 9.2%) was 12%/13% ahead of expectations. Adj. EBIT reached € 46.0m (-27.1% y-o-y, margin 9.7%) and was 14%/18% vs consensus. EPS of € 0.42 compares to expectations of € 0.29 and € 0.34 for the consensus driven by a better financial result.Oph...Carl Zeiss Meditec is a holding company. Co.'s businesses are focused on two primary areas: Ophthalmology and Microsurgery. In Ophthalmology, Co.'s operations are divided in to two strategic business units: Ophthalmic Systems, which includes a range of laser and diagnostic systems for ophthalmology; and Surgical Ophthalmology, which consists of activities in the field of ophthalmic implants and consumables. In Microsurgery, Co. provides surgical microscopes and visualization solutions, e. g. for ear, nose and throat surgery, or neurosurgery. These products are mainly used to assist with the removal of tumors, as well as the treatment of vascular diseases and functional disorders.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.